MN Legislative Updates: Senate File 3591 (SF3591) 2026 Proposed bill that tightens THC limits and retail rules for cannabis and hemp products

Carpfish Creative
16 hours ago
5 min read

Senate File 3591 (SF 3591) is a 2026 Minnesota Senate bill that tightens THC limits and retail rules for cannabis and hemp products.

The bill title and summaries describe it as:

Establishing THC potency limits for:
- Cannabis concentrate
- Cannabis flower
- Topical or transdermal hemp products
Setting retail location requirements (where these products can be sold).
Creating product labeling requirements for those items.

Industry trackers also describe it as a new framework for hemp‑derived cannabinoid product standards, licensing, and compliance, with a focus on potency and consumer protection.

Status and committee (early 2026)

Introduced: February 17, 2026.
Current status: In the Minnesota Senate, referred to the Commerce and Consumer Protection Committee after first reading.
No votes yet: As of the latest status, it has not yet passed the Senate or House.

Hearing dates

The only formal action on record so far is the referral to Senate Commerce and Consumer Protection on Feb 17, 2026. That means:

No specific hearing date is listed in the bill history itself yet.
Upcoming hearings will appear on:
- The bill’s status/history page is once scheduled.
- The Senate “All Committees’ Hearings Schedule” (look under Commerce and Consumer Protection, and search for “SF 3591”).

Because agendas can be posted and changed quickly, you’ll want to check those two places regularly.

Who is carrying it / who to contact

Chief author: SF 3591’s primary sponsor is Sen. Matt Klein (DFL–53).
Co‑authors: Additional Senate co‑sponsors are listed on the SF 3591 sponsors page.

For advocacy or questions, typical contacts are:

Sen. Matt Klein – as chief author, via his Senate member page (email, phone, office address listed there).
Senate Commerce and Consumer Protection Committee – chair, vice‑chair, ranking minority member, and committee administrator; their contact info and testimony instructions are on the committee’s page, and hearings will be listed on the Senate “All Committees’ Hearings Schedule.”

If you tell me your role (hemp retailer, cultivator, city official, etc.), I can draft a concise email you can send to Sen. Klein and the Commerce Committee about SF 3591.

Version 1: For Cannabis/Hemp Business Owners

Subject: Concerns Regarding SF 3591 – Impact on Minnesota Cannabis Businesses

Dear Senator Klein and Members of the Senate Commerce and Consumer Protection Committee,

My name is [Your Name], and I am the [owner/operator] of [Business Name], a [license type: microbusiness/retailer/cultivator/hemp manufacturer, etc.] located in [City, Minnesota]. I am writing to express my concerns regarding Senate File 3591, which proposes new THC potency limits, retail location requirements, and labeling standards for cannabis and hemp products.

While I support responsible regulation that protects consumers, I am concerned that SF 3591 may have unintended consequences for Minnesota's emerging cannabis industry:

1. Economic Impact on Small Businesses

Many Minnesota cannabis businesses—especially microbusinesses and social equity licensees—are still in the startup phase following the February 2025 licensing round.
New potency limits and retail restrictions could force costly product reformulations, inventory losses, and compliance expenses at a time when businesses are working to achieve financial stability.
[Optional: Add your specific concern, e.g., "Our business has invested $X in compliant products that may become non-compliant under these new limits."]

2. Market Competitiveness and Consumer Safety

Overly restrictive potency limits may push consumers toward unregulated or illicit products, undermining the state's goal of creating a safe, regulated market.
Minnesota's cannabis industry is already competing with neighboring states and unlicensed sellers; additional restrictions could disadvantage legal operators.

3. Need for Stakeholder Input

The cannabis industry is highly technical, and regulations affecting potency, testing, and labeling should be developed in consultation with licensed businesses, testing labs, and the Office of Cannabis Management (OCM).
I respectfully request that the committee hold stakeholder meetings or accept public testimony to ensure the bill reflects industry best practices and on-the-ground realities.

4. Implementation Timeline

If SF 3591 moves forward, I urge the committee to include a reasonable implementation period (at least 12–18 months) to allow businesses to comply without financial hardship.
Clear guidance from OCM will be essential to ensure consistent enforcement across all license types.

My Request:I respectfully ask that you:

Delay action on SF 3591 until comprehensive stakeholder input can be gathered.
Amend the bill to include reasonable phase-in periods and small business protections.
Coordinate with OCM to ensure the bill aligns with existing Chapter 342 regulations and does not conflict with local zoning or retail registration processes.

I appreciate your leadership on cannabis policy and your commitment to building a fair, safe, and sustainable industry in Minnesota. I am happy to provide additional information, testify at a hearing, or discuss this matter further at your convenience.

Thank you for your time and consideration.

Respectfully,

[Your Full Name]

[Business Name & License Type]

[Street Address]

[City, State, ZIP]

[Phone Number]

[Email Address]

Version 2: For Supporters/Advocates (Non-Business Owners)

Subject: Public Comment on SF 3591 – Cannabis Potency and Retail Restrictions

Dear Senator Klein and Members of the Senate Commerce and Consumer Protection Committee,

My name is [Your Name], and I am a resident of [City, Minnesota] and a supporter of Minnesota's legal cannabis market. I am writing to share my concerns about Senate File 3591, which proposes new THC potency limits and retail location requirements for cannabis and hemp products.

While I understand the goal of consumer protection, I believe SF 3591 may have unintended negative consequences:

1. Access to Effective Products

Many medical cannabis patients and adult-use consumers rely on higher-potency products for symptom relief, pain management, or personal wellness.
Arbitrary potency caps may force consumers to purchase larger quantities or turn to unregulated sources, increasing safety risks.

2. Harm Reduction and Public Safety

Minnesota's regulated cannabis market was designed to eliminate the illicit market by offering safe, tested, and labeled products.
Overly restrictive limits could drive consumers back to unregulated sellers, undermining public safety and tax revenue.

3. Equity and Small Business

Minnesota's cannabis law prioritizes social equity applicants and small businesses. New restrictions could disproportionately harm these operators, who are already navigating significant startup challenges.
I urge the committee to consider the impact on microbusinesses and social equity licensees before advancing this bill.

4. Need for Evidence-Based Policy

I encourage the committee to review data from other states (Colorado, Washington, Oregon) that have implemented potency limits, and to consult with public health experts, the Office of Cannabis Management, and licensed businesses before finalizing these standards.